Big companies love acronyms, and Pfizer is no exception. So when I heard the world’s biggest drugmaker talk about using its CTI network to validate POMs, it sounded like some Dilbert-style, soul-crushing initiative going nowhere. Writing off this latest initiative would be the safe bet, as many have tried and failed to revitalize the unproductive business of early-stage drug development.
